Scynexis (SCYX) Non-Current Assets (2013 - 2026)
Scynexis' (SCYX) quarterly Non-Current Assets came in at $18.7 million in Q2 2026, up 346.47% on a YoY basis from $4.2 million in Q2 2025, and up 25.44% quarter-over-quarter from $14.9 million in Q1 2026.
Analysis
Scynexis (SCYX) Non-Current Assets (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Non-Current Assets for 14 consecutive years, with $18.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets rose 346.47% year-over-year to $18.7 million; the trailing twelve-month figure through Jun 2026 stood at $54.7 million (down 3.91% YoY), and the FY2025 full-year result was $18.7 million, up 1.03% from the prior year.
- Non-Current Assets advanced to $18.7 million in Q2 2026 per SCYX's latest filing, from $14.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $26.3 million in Q4 2023 and bottomed at $2.4 million in Q3 2025.
- Historically, Non-Current Assets has averaged $13.6 million across 5 years, with a median of $14.1 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets plunged 87.2% in 2025, then surged 346.47% in 2026.
- Over 5 years, Non-Current Assets stood at $8.7 million in 2022, then soared by 200.56% to $26.3 million in 2023, then retreated by 29.79% to $18.5 million in 2024, then increased by 1.03% to $18.7 million in 2025, then gained by 0.43% to $18.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $18.7 million, $14.9 million, and $18.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 18.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.73 Mn |
| Mar 31, 2026 | 14.94 Mn |
| Dec 31, 2025 | 18.65 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 4.20 Mn |
| Mar 31, 2025 | 15.69 Mn |
| Dec 31, 2024 | 18.46 Mn |
| Sep 30, 2024 | 18.58 Mn |
| Jun 30, 2024 | 13.23 Mn |
| Mar 31, 2024 | 16.58 Mn |
| Dec 31, 2023 | 26.30 Mn |
| Sep 30, 2023 | 19.91 Mn |
| Jun 30, 2023 | 9.33 Mn |
| Mar 31, 2023 | 10.53 Mn |
| Dec 31, 2022 | 8.75 Mn |
| Sep 30, 2022 | 8.73 Mn |
| Jun 30, 2022 | 9.94 Mn |
| Mar 31, 2022 | 9.66 Mn |
| Dec 31, 2021 | 10.46 Mn |
| Sep 30, 2021 | 5.95 Mn |